Insider Monkey
Apellis Post Hoc Analysis Confirms Long-Term Benefit of SYFOVRE for Geographic Atrophy
📈
AI Sentiment
Highly Positive
8/10
- Home
- APLS
as of 12-05-2025 3:59pm EST
$23.62
+$1.43
+6.44%
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Chart Type:
Time Range:
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 2.7B | IPO Year: | 2017 |
| Target Price: | $33.11 | AVG Volume (30 days): | 2.4M |
| Analyst Decision: | Buy | Number of Analysts: | 19 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $16.10 - $35.72 | Next Earning Date: | 10-30-2025 |
| Revenue: | $1,016,397,000 | Revenue Growth: | 42.11% |
| Revenue Growth (this year): | 29% | Revenue Growth (next year): | -12.26% |
AI-Powered APLS Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 74.34%
74.34%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Apellis Pharmaceuticals Inc. (APLS)
Watson David O.
Sell
General Counsel
APLS Nov 17, 2025
Avg Cost/Share
$20.06
Shares
5,000
Total Value
$100,300.00
Owned After
108,730
SEC Form 4
Sullivan Timothy Eugene
Sell
Chief Financial Officer
APLS Oct 21, 2025
Avg Cost/Share
$28.03
Shares
10,000
Total Value
$280,300.00
Owned After
110,936
SEC Form 4
Watson David O.
Sell
General Counsel
APLS Oct 16, 2025
Avg Cost/Share
$25.22
Shares
5,000
Total Value
$126,100.00
Owned After
108,730
SEC Form 4
Dunlop A. Sinclair
Sell
Director
APLS Oct 10, 2025
Avg Cost/Share
$23.72
Shares
31,092
Total Value
$737,536.44
Owned After
3,837
SEC Form 4
Dunlop A. Sinclair
Sell
Director
APLS Sep 30, 2025
Avg Cost/Share
$22.58
Shares
31,092
Total Value
$702,057.36
Owned After
3,837
SEC Form 4
Watson David O.
Sell
General Counsel
APLS Sep 16, 2025
Avg Cost/Share
$24.34
Shares
5,000
Total Value
$121,700.00
Owned After
108,730
SEC Form 4
Chopas James George
Sell
VP/Chief Accounting Officer
APLS Sep 15, 2025
Avg Cost/Share
$24.19
Shares
189
Total Value
$4,572.29
Owned After
53,468
SEC Form 4
Watson David O.
Sell
General Counsel
APLS Sep 10, 2025
Avg Cost/Share
$26.17
Shares
20,000
Total Value
$523,400.00
Owned After
108,730
SEC Form 4
Sullivan Timothy Eugene
Sell
Chief Financial Officer
APLS Sep 8, 2025
Avg Cost/Share
$27.85
Shares
42,729
Total Value
$1,190,129.94
Owned After
110,936
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Watson David O. | APLS | General Counsel | Nov 17, 2025 | Sell | $20.06 | 5,000 | $100,300.00 | 108,730 | |
| Sullivan Timothy Eugene | APLS | Chief Financial Officer | Oct 21, 2025 | Sell | $28.03 | 10,000 | $280,300.00 | 110,936 | |
| Watson David O. | APLS | General Counsel | Oct 16, 2025 | Sell | $25.22 | 5,000 | $126,100.00 | 108,730 | |
| Dunlop A. Sinclair | APLS | Director | Oct 10, 2025 | Sell | $23.72 | 31,092 | $737,536.44 | 3,837 | |
| Dunlop A. Sinclair | APLS | Director | Sep 30, 2025 | Sell | $22.58 | 31,092 | $702,057.36 | 3,837 | |
| Watson David O. | APLS | General Counsel | Sep 16, 2025 | Sell | $24.34 | 5,000 | $121,700.00 | 108,730 | |
| Chopas James George | APLS | VP/Chief Accounting Officer | Sep 15, 2025 | Sell | $24.19 | 189 | $4,572.29 | 53,468 | |
| Watson David O. | APLS | General Counsel | Sep 10, 2025 | Sell | $26.17 | 20,000 | $523,400.00 | 108,730 | |
| Sullivan Timothy Eugene | APLS | Chief Financial Officer | Sep 8, 2025 | Sell | $27.85 | 42,729 | $1,190,129.94 | 110,936 |
Latest Apellis Pharmaceuticals Inc. News
APLS Breaking Stock News: Dive into APLS Ticker-Specific Updates for Smart Investing
Compare APLS vs Leading Stocks
See how APLS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "APLS Apellis Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.